TELEFLEX INC 8-K

What Happened

• Teleflex Incorporated announced its financial results for the quarter ended March 31, 2026 via a press release dated May 7, 2026, which is furnished as Exhibit 99.1 to the Form 8-K. The company also made an earnings slide presentation (Exhibit 99.2) available in advance of a conference call on May 7, 2026. The Form 8‑K was signed by CFO John R. Deren.
• The press release includes both GAAP results and several non‑GAAP measures that Teleflex uses to assess performance, including pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, and adjusted diluted earnings per share.

Key Details

• Filing date: May 7, 2026; period reported: quarter ended March 31, 2026. Exhibits: 99.1 (press release) and 99.2 (slide presentation).
• Pro forma adjustments: exclude certain products discontinued during the year ended Dec 31, 2025 (strategic realignment) and reflect the Vascular Intervention business acquisition from BIOTRONIK as if it occurred Jan 1, 2025.
• Adjusted diluted EPS adjustments may exclude restructuring/optimization charges, impairments, acquisition/integration/divestiture items, separation costs tied to Strategic Divestitures (Acute Care, Interventional Urology, OEM), increased reserves related to an Italian payback, EU MDR device registration costs, intangible amortization, ERP/IT transition costs, and certain tax adjustments.
• Management states non‑GAAP measures are used for internal decision‑making and period‑to‑period comparisons but cautions they are supplemental to GAAP and may not be comparable to other companies’ measures.

Why It Matters

• Retail investors should know the company is presenting both GAAP and adjusted (non‑GAAP/pro forma) results and explicitly applying pro forma treatment for a significant acquisition and recent product discontinuations—these adjustments can materially affect reported revenue growth and EPS comparisons.
• The filing highlights ongoing strategic moves (acquisition integration and planned divestitures) and one‑time or non‑recurring items (separation costs, ERP/IT costs, EU MDR work) that management excludes from adjusted metrics; investors should review the press release and slide deck (Exhibits 99.1/99.2) for the actual GAAP figures and reconciliations to understand underlying trends.